



Institutional Biosafety Committee

UNTHSC IBC Meeting Minutes November 19, 2025 12:03 pm – 1:05 pm Teams meeting

Members in Attendance

Rance Berg – IBC Chair
Anne-Sophie Brocard (IBC vice Chair, UNTHSC member)
Egeenee Daniels -UNTHSC member
Jayoung Kim - UNTHSC member
Richard McKee- UNTHSC member
Christopher Parker (Community member)
Raghu Krishnamoorthy - UNTHSC member

Members Absent

Maya Nair -BSO, *IBC Coordinator*
Mike Chumley (Community member)

Quorum – Present

Other individual in Attendance

Tania Ghani (Assistant Vice President, Research Compliance)

IBC Chair called the meeting to order at 12:03 PM

The IBC Chair reminded all members present to identify any conflicts of interest as each registration is reviewed.

I. Minutes Approval:

October meeting minutes were approved
Yes: 6 No: 0 Abstained: 0 Total:6 Recusals: 0

II. Discussions of prior business and updates to the committee:

The 2025 Biosafety Manual was approved with the following corrections

- Correct rebranding of UNT Health
- Typos correction

Yes: 6 No: 0 Abstained: 0 Total:6 Recusals: 0

The committee approved the new version of the laboratory audit questionnaire

Yes: 6 No: 0 Abstained: 0 Total:6 Recusals: 0

Dr. Brocard presented the updated process for injury reporting and locations to seek medical attention. A memo will be sent to all IBC PIs on behalf of the IBC to serve as an amendment to their protocol.

Yes: 6 No: 0 Abstained: 0 Total:6 Recusals: 0

NIH biosafety strengthening project will resume listening sessions in early Dec with region #2

III. Submissions for Convened Review – 1

1. Protocol Number: IBC/rDNA/AB/2025-1
 Protocol Title: Signal Transduction Pathways and Human Disorders
 PI: Alakananda Basu, PhD
 Biosafety Level: BSL2
 NIH Category: IIID1, D3, E, F8
 Committee recommendation: RMTSA with designated reviewers Drs. Nair, Berg, and Brocard,
 Vote: Yes: 6 No: 0 Abstained: 0 Total:8 Recusals: 0

Modifications requested:

The following modifications are requested to secure approval:

- Section #4 indicate who will be handling the human material
- Section #6 provide more information about how the different cell lines are used with the different vectors, CMV not listed. Complete the second table.
- Section #7 change “lab jacket” to “lab coat”
- Section #8 change “1013PFU” to “10E13PFU”.
 - provide more information about Si RNA origin and use.
 - Indicate how *E. coli* will be used
 - Indicate how additional retrovirus will be propagated and where the helper plasmid will come from.
 - Clarify if cloning will be performed or if retroviruses are obtained ready to use.
 - Need more information about the different lentiviruses and retroviruses used, including competency status.
 - Change Wescodyne to 10% bleach and/or Cavicide.
- Section VI. Material should not be transported in Styrofoam box but hard sided plastic one.
- Recombinant section
 - complete the table for each agent individually
 - In the NIH guideline section change D from N to Y and G from Y to N

2- Amendments for review

1. Protocol Number: IBC/rDNA/DS/2024-1
 Protocol Title: Use of Adeno-associated Viruses Type 2 for Neuroprotection in Glaucoma
 PI: Dorota L. Stankowska, PhD
 Biosafety Level: BSL2
 NIH Category: IIID3
Change of PI to Dr. Raghu Krishnamoorthy, PhD.
Dr. Stankowska is leaving UNT Health and is transferring her IBC protocol to Dr. Krishnamoorthy. Dr. Krishnamoorthy is currently listed on her protocol as staff and has collaborated on the project. The grants are being transferred to Dr. Krishnamoorthy as well.
 Committee recommendation: approved
 Vote: Yes: 6 No: 0 Abstained: 0 Total:8 Recusals: 0
2. Protocol Number: IBC/rDNA/TT/2023-1
 Protocol Title: Tissue remodeling in human and mouse eye tissues and cells
 PI: Tara Tovar-Vidales, PhD
 Biosafety Level: BSL2
 NIH Category: none
Addition of normal and glaucoma monkey eyes, including deriving primary cell culture derived from these eyes to the existing biological materials protocol
Dr. Tovar-Vidales is getting monkey eyes sourced from St. Kitts Green Monkey Colony on Cayo Santiago Island (Puerto Rico).
 Committee recommendation: Denied with the following conditions

- Need more information about the exact source of the Monkeys, colony or wild caught, status of the monkey from Herpes B infections, what precautions are being taken to prevent Herpes B infections to staff, need to get complete SOP on dissection of the eyes and cell preparation, MTA needs to be in place.

Vote:

Yes: 6 No: 0 Abstained: 0 Total:8 Recusals: 0

IV. Response to Requires Modification to Secure Approval- None

PI	Protocol approval date	Title	Protocol number
Mark Pulse	11/4/2025	Culturing Enterobacteriaceae for use in animal models and in vitro susceptibility testing	IBC/p/MP/2025-2

V. Amendments approved Administratively:

None


Public comments: There were no public comments.**Adjournment:** IBC chair moved to Adjourn the meeting at 1:05PM**IBC Chair****Name:** Rance Berg, PhD

Signed by:

 4E3708F2FE464AA...

Signature: Date:12/18/2025**IBC Coordinator**

Anne-Sophie Brocard PhD, CBSP (ABSA)

Signed by:

 1422CA7ED8DF486...

12/18/25